These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30737104)

  • 1. The critical need for clinical decision support systems for identification and management of teratogenic medications.
    DiPietro Mager NA
    J Am Pharm Assoc (2003); 2019; 59(2S):S18-S20. PubMed ID: 30737104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of reproductive life plans in identification of potentially teratogenic medication use: A pilot study.
    DiPietro Mager N; Mills C; Snelling A
    Birth; 2018 Mar; 45(1):50-54. PubMed ID: 29052257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial.
    Schwarz EB; Parisi SM; Handler SM; Koren G; Cohen ED; Shevchik GJ; Fischer GS
    J Gen Intern Med; 2012 Jul; 27(7):831-8. PubMed ID: 22297687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives of primary care clinicians on teratogenic risk counseling.
    Schwarz EB; Santucci A; Borrero S; Akers AY; Nikolajski C; Gold MA
    Birth Defects Res A Clin Mol Teratol; 2009 Oct; 85(10):858-63. PubMed ID: 19591115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counseling about medication-induced birth defects with clinical decision support in primary care.
    Schwarz EB; Parisi SM; Handler SM; Koren G; Shevchik G; Fischer GS
    J Womens Health (Larchmt); 2013 Oct; 22(10):817-24. PubMed ID: 23930947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women's perspectives on counseling about risks for medication-induced birth defects.
    Santucci AK; Gold MA; Akers AY; Borrero S; Schwarz EB
    Birth Defects Res A Clin Mol Teratol; 2010 Jan; 88(1):64-9. PubMed ID: 19637252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers.
    Eisenberg DL; Stika C; Desai A; Baker D; Yost KJ
    J Gen Intern Med; 2010 Apr; 25(4):291-7. PubMed ID: 20087677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy.
    Bhakta J; Bainbridge J; Borgelt L
    Epilepsy Behav; 2015 Nov; 52(Pt A):212-7. PubMed ID: 26460786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Innovative Framework to Improve Teratogenic Medication Risk Counseling.
    Shroff S; McNeil M; Borrero S
    J Midwifery Womens Health; 2017 May; 62(3):353-357. PubMed ID: 28485536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription of teratogenic medications in United States ambulatory practices.
    Schwarz EB; Maselli J; Norton M; Gonzales R
    Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk management of teratogenic medicines: A systematic review.
    Shroukh WA; Steinke DT; Willis SC
    Birth Defects Res; 2020 Dec; 112(20):1755-1786. PubMed ID: 32918401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems.
    Main C; Moxham T; Wyatt JC; Kay J; Anderson R; Stein K
    Health Technol Assess; 2010 Oct; 14(48):1-227. PubMed ID: 21034668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provision of potentially teratogenic medications to female veterans of childbearing age.
    Schwarz EB; Longo LS; Zhao X; Stone RA; Cunningham F; Good CB
    Med Care; 2010 Sep; 48(9):834-42. PubMed ID: 20706159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.
    Schwarz EB; Postlethwaite DA; Hung YY; Armstrong MA
    Ann Intern Med; 2007 Sep; 147(6):370-6. PubMed ID: 17876020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human teratogens: update 2010.
    Holmes LB
    Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraceptive Provision to Adolescent Females Prescribed Teratogenic Medications.
    Stancil SL; Miller M; Briggs H; Lynch D; Goggin K; Kearns G
    Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26676050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the electronic medical record to refer women taking category D or X medications for teratogen and contraceptive counseling.
    Mody SK; Wu J; Ornelas M; Kernahan C; Salas E; Kao K; Felix R; Chambers C
    Birth Defects Res A Clin Mol Teratol; 2015 Jul; 103(7):644-7. PubMed ID: 26100297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Student and educator experiences of maternal-child simulation-based learning: a systematic review of qualitative evidence protocol.
    MacKinnon K; Marcellus L; Rivers J; Gordon C; Ryan M; Butcher D
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):14-26. PubMed ID: 26447004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities missed: improving the rate of contraceptive counseling or provision when prescribing reproductive-aged women potentially teratogenic medications in a family medicine resident clinic.
    Fritsche MD; Ables AZ; Bendyk H
    Contraception; 2011 Oct; 84(4):372-6. PubMed ID: 21920192
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.